Merck feels pain of Schering ops integration

Difficulties integrating the manufacturing and supply chain operations of two big pharma companies is crimping the supply of women's health products. As Merck continues to swallow Schering-Plough following the late 2009 acquisition, legacy systems and processes are proving a hindrance to efforts aimed at operations consistency.

The drugmaker says it's been managing through temporary supply shortages of some women's health products since the end of last year, Dow Jones reports. It's "working to resolve these issues."

Plans announced last year included the closing of eight manufacturing plants as well as R&D sites for cost savings. The news outlet reports Merck has also faced manufacturing and supply problems in its vaccine operations.

- here's the story

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.